Yavuz Turgut Gederet

Yavuz Turgut Gederet

Auto-generated profile, based on publicly available information

Yavuz Turgut Gederet

Saglik Bilimleri Universitesi

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2015 in Endokrynologia Polska
Verified
Journal Article
Open access
PDF file
ZIZeynep Ozturk Inal
Zeynep Ozturk Inal
SESami Erdem
Sami Erdem
YGYavuz Gederet
Yavuz Gederet
CDCevdet Duran
Cevdet Duran
ZKZehra Kucukaydin
Zehra Kucukaydin
DSDerya Kilic Sakarya
Derya Kilic Sakarya
Introduction: The aim of this study was to evaluate the effects of polycystic ovary syndrome (PCOS) and body mass index (BMI) on serum adropin and ischemia modified albumin (IMA) levels. Materials and methods: This prospective cross-sectional study was performed with a total of 120 women [group1; non-PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30) and group 2; PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30)]. Blood samples were collected between the third and fifth days of the women’s menstrual cycles after a night of fasting. Results: There were no differences between the groups in relation to age, basal follicle stimulating hormone, estradiol, thyroid stimulating hormone, prolactin, high-density lipoprotein cholesterol, total testosterone, dehydroepiandrosterone sulfate levels, systolic and diastolic blood pressures. A significant difference was found in basal luteinizing hormone, fasting glucose, insulin, homeostatic model assessment of insulin resistance, total cholesterol, low-density lipoprotein cholesterol, triglycerides, free testosterone levels, waist-to-hip ratios and the Ferriman-Gallwey scores between the PCOS and non-PCOS patients in the lean and overweight groups (p<0.05). The serum adropin levels in the lean PCOS group were lower than in the lean non-PCOS group (p<0.05) and were lower in the overweight PCOS group than in the overweight non-PCOS group (p<0.05). There was also a statistically significant difference in serum IMA levels in the PCOS group than in the non-PCOS group in both the lean and overweight groups (p<0.05). Conclusions: Although serum adropin levels were significantly decreased in the PCOS group, IMA levels increased. Further studies are needed to determine the effects of adropin and IMA in women with PCOS and to use a new marker to monitorize treatment outcomes. Introduction: The aim of this study was to evaluate the effects of polycystic ovary syndrome (PCOS) and body mass index (BMI) on serum adropin and ischemia modified albumin (IMA) levels. Materials and methods: This prospective cross-sectional study was performed with a total of 120 women [group1; non-PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30) and group 2; PCOS = 60 (BMI <25 = 30, BMI ≥25 = 30)]. Blood samples were collected between the third and fifth days of the women’s menstrual cycles after a night of fasting. Results: There were no differences between the groups in relation to age, basal follicle stimulating hormone, estradiol, thyroid stimulating hormone, prolactin, high-density lipoprotein cholesterol, total testosterone, dehydroepiandrosterone sulfate levels, systolic and diastolic blood pressures. A significant difference was found in basal luteinizing hormone, fasting glucose, insulin, homeostatic model assessment of insulin resistance, total cholesterol, low-density lipoprotein cholesterol, triglycerides, free testosterone levels, waist-to-hip ratios and the Ferriman-Gallwey scores between the PCOS and non-PCOS patients in the lean and overweight groups (p<0.05). The serum adropin levels in the lean PCOS group were lower than in the lean non-PCOS group (p<0.05) and were lower in the overweight PCOS group than in the overweight non-PCOS group (p<0.05). There was also a statistically significant difference in serum IMA levels in the PCOS group than in the non-PCOS group in both the lean and overweight groups (p<0.05). Conclusions: Although serum adropin levels were significantly decreased in the PCOS group, IMA levels increased. Further studies are needed to determine the effects of adropin and IMA in women with PCOS and to use a new marker to monitorize treatment outcomes.

1 April 2018
Verified
Journal Article
Closed access
ISI Solak
I Solak
CCC. D. Cetinkaya
C. D. Cetinkaya
YGY. T. Gederet
Y. T. Gederet
BKB. Kozanhan
B. Kozanhan
OEO. Erel
O. Erel
MEM. A. Eryilmaz
M. A. Eryilmaz

1 September 2002
Verified
Journal Article
Closed access
AIAbdullah Içli
Abdullah Içli
HGHasan Gök
Hasan Gök
BABülent B Altunkeser
Bülent B Altunkeser
KOKurtuluş Ozdemir
Kurtuluş Ozdemir
MGMehmet Gürbilek
Mehmet Gürbilek
GSGülizar Sökmen
Gülizar Sökmen

4 October 2018 in Family Practice and Palliative Care
Verified
Journal Article
Open access
PDF file
ISİbRahim Solak
İbRahim Solak
KMKamile Marakoǧlu
Kamile Marakoǧlu
SPSelma Pekgor
Selma Pekgor
NKNisa Cetin Kargi̇n
Nisa Cetin Kargi̇n
YGYavuz Turgut Gederet
Yavuz Turgut Gederet
MEMehmet Ali Eryi̇lMaz
Mehmet Ali Eryi̇lMaz
Introduction: This study aimed to evaluate the changes both in the systemic inflammation and in the mucociliary clearance following smoking cessation, and their associations with smoking characteristics.Methods: A total of 30 cases admitted to Konya Training and Research Hospital, University of Health Sciences, Department of Smoking Cessation were recruited, and 27 of them completed the study. Tumor necrosis factor alpha (TNF-α), interleukin (IL) -4, IL-6, IL-8, IL-10 and saccharin transit time (STT) was measuredat the beginning and 2 months after smoking cessation.Results: We found in this study that STT decreased significantly in 2 months after cessation (p<0.001). In our study, we found that serum TNF-α (p=0.035) and IL-8 (p=0.002) levels were decreased significantly at 2 months after quitting when compared with the basal levels. In our study, serum IL-6 (p=0.132) and IL-10 (p=0.657) levels did not change significantly in the 2nd month of quitting, when compared to basal levels.Conclusion: In this study, two months after smoking cessation, nasal mucosal clearance and systemic inflammatory response especially plasma TNF- α and IL-8 levels were improved. We think that further studies with larger sample size and longer follow-up will provide more detailed data about the improvements in systemic inflammation.

27 May 2021 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
SESami Erdem
Sami Erdem
KYKamile YÜCEL
Kamile YÜCEL
YGYavuz Turgut Gederet
Yavuz Turgut Gederet
EKErcan Kurti̇pEk
Ercan Kurti̇pEk
TBTaha Tahir Bekçi̇
Taha Tahir Bekçi̇
HKHüseyin Kurku
Hüseyin Kurku
Background: Pulmonary embolism (PE) is a serious clinical condition and difficult to be diagnosed. The aim of the present study was to evaluate serum adropin and ischemia-modified albumin (IMA) levels in the patients with PE. Materials and Methods: The study consisted of 109 participants, including 50 patients with PE and 59 healthy individuals. The patients diagnosed with PE through computed tomography pulmonary angiography (CTPA) were included into the study. Serum adropin and IMA concentrations were measured by an enzyme-linked immunosorbent assay kit. Results: The patients with PE had higher serum adropin (607.5±205.1 ng/mL) and lower IMA (2128.6±801.8 ng/mL), compared with those in the controls (505.5±231.3 ng/mL and 2466.9±1044.9 ng/mL, respectively); however, the difference was not significant. In the study, we found a weak and negative correlation between adropin and IMA levels in the patients with PE (p=0.020, r=-0.348). Conclusions: In our study among the patients with PE, there was no significant difference between adropin and IMA levels, although serum atropin concentration was high, and IMA concentration was low. So, we consider that both IMA and adropin are the inappropriate markers for the diagnosis of PE.